rxstatShortages › Norethindrone

Norethindrone shortage status

Partial shortage

Source: Health Canada shortage reports · Updated Jul 9, 2026

Some Norethindrone products are in shortage in Canada (1 of 4 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Aug 10, 2026.
Products affected
1 / 4
In shortage since
Dec 1, 2025
Est. full return
Aug 10, 2026
Reports on file
13
Talk to your pharmacist. Pharmacists can often substitute another manufacturer's version, a different strength, or (in most provinces) adapt or renew a prescription on the spot. Your free provincial health line is 811.

Reports by product

Active shortage
MAEVE
0.35MG · TABLET · GLENMARK PHARMACEUTICALS CANADA INC.
DIN 02458683 · since Dec 1, 2025, est. end Aug 10, 2026 · Demand increase for the drug.
Resolved
MOVISSE
0.35MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02410303 · ended Jul 6, 2022 · Disruption of the manufacture of the drug.
Resolved
MOVISSE
0.35MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02410303 · ended Dec 30, 2021 · Demand increase for the drug.
To be discontinued
MICRONOR TABLETS 28-DAY
0.35MG · TABLET · JANSSEN INC
DIN 00037605
To be discontinued
MICRONOR TABLETS 28-DAY
0.35MG · TABLET · JANSSEN INC
DIN 00037605
Resolved
MOVISSE
0.35MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02410303 · ended Apr 28, 2020 · Demand increase for the drug.
Resolved
MOVISSE
0.35MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02410303 · ended Feb 25, 2020 · Delay in shipping of the drug.
Resolved
MOVISSE
0.35MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02410303 · ended Jan 22, 2020 · Delay in shipping of the drug.
Resolved
JENCYCLA
0.35MG · TABLET · LUPIN PHARMA CANADA LIMITED
DIN 02441306 · ended Jan 21, 2020 · Demand increase for the drug.
Resolved
MOVISSE
0.35MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02410303 · ended Aug 30, 2019 · Requirements related to complying with good manufacturing practices.
Avoided
MOVISSE
0.35MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02410303 · ended Feb 9, 2018 · Delay in shipping of the drug.
Resolved
JENCYCLA
0.35MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02441306 · ended Dec 11, 2017 · Demand increase for the drug.

Showing 12 of 13 reports. All reports are on file with Health Canada.

What's happening

Norethindrone is currently affected by an active shortage report filed with Health Canada by GLENMARK PHARMACEUTICALS CANADA INC..

The reported cause is: demand increase for the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.

If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.

Norethindrone is classified under “HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE” (ATC G03AC).

Recent changes

Common questions

When will Norethindrone be back in stock in Canada?

The latest manufacturer estimate is Aug 10, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.

Why is Norethindrone in shortage?

See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Related drugs (hormonal contraceptives for systemic use)

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.